---
title: "Astrazeneca establishes a global R&D strategic center in Beijing"
description: "Astrazeneca officially launched its Global R&D Beijing Strategic Center on the 25th, which is its sixth global and second strategic R&D center in China, aimed at accelerating the translation of early "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262774041.md"
published_at: "2025-10-26T12:06:21.000Z"
---

# Astrazeneca establishes a global R&D strategic center in Beijing

> Astrazeneca officially launched its Global R&D Beijing Strategic Center on the 25th, which is its sixth global and second strategic R&D center in China, aimed at accelerating the translation of early drug research results into clinical development. At the same time, Astrazeneca has reached cooperation agreements with the University of Cambridge and relevant institutions in Beijing to promote bilateral connections between China and the UK, emphasizing the importance of China as an internal source of innovation

On the 25th, AstraZeneca officially launched its Global R&D Beijing Strategic Center, which is AstraZeneca's sixth global and second strategic R&D center in China, aimed at accelerating the translation of early drug research results into clinical development. AstraZeneca also announced collaborations with the University of Cambridge, the Beijing Municipal Science and Technology Commission, the Management Committee of Zhongguancun Science Park, and the Management Committee of Beijing Economic and Technological Development Area. AstraZeneca's UK Chairman, Pascal Soriot, stated that this collaboration will bring together experts and professional capabilities, establish a two-way connection between Beijing and the University of Cambridge, and achieve "in China, for China," as well as "in China, for the world," viewing China as a true internal source of innovation while also engaging in external cooperation in China

### Related Stocks

- [AZN.US - AstraZeneca](https://longbridge.com/en/quote/AZN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 斥资 185 亿美元牵手石药集团后，阿斯利康每股收益预增双位数 | 阿斯利康预计 2026 年每股收益将实现两位数增长，肿瘤药物销售强劲有望抵消糖尿病药物专利到期影响。公司近期以高达 185 亿美元引入石药集团长效肽技术，加速布局 GLP-1 减肥药市场。尽管面临美国药价政策调整，公司通过协议获得关税豁免。 | [Link](https://longbridge.com/en/news/275425282.md) |
| 阿斯利康预计 2026 年的核心每股收益将实现低双位数百分比的增长 | 阿斯利康制药预计其核心每股收益将在 2026 年增长低双位数百分比。该公司预计 2025 财年的总收入增长将在中到高个位数之间，并已宣布每股 2.17 美元的第二次中期股息。此外，2025 财年的总股息已增加 3%，达到每股 3.20 美元 | [Link](https://longbridge.com/en/news/275415782.md) |
| 奔驰中国换帅，告别 “段建军时代” | 首位本土高管身退。 | [Link](https://longbridge.com/en/news/275976978.md) |
| 每千次展示 60 美元！OpenAI 用高价拉开 “AI 广告” 大幕 | 为应对 AI 巨额开支，OpenAI 正式测试广告，CPM60 美元起步、最低投入 20 万美元，定位高端渠道，直接挑战谷歌万亿美元市场，WPP 等顶级代理已率先合作。但转型风险并存：需平衡用户信任，承诺不用私聊数据；对手 Anthropi | [Link](https://longbridge.com/en/news/275993077.md) |
| REG - 摩根大通 Claver IT - 十大投资项目 | JPMorgan Claverhouse Investment Trust PLC 已公布截至 2026 年 1 月 30 日的十大投资。主要持股包括汇丰控股有限公司（9.3%）、壳牌公司（6.3%）、阿斯利康集团（5.5%）、纳特威斯特集 | [Link](https://longbridge.com/en/news/275885617.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.